215 related articles for article (PubMed ID: 33327998)
1. [Clinical significance of minimal residual disease in B-lineage acute lymphoblastic leukemia pediatric patients with different fusion gene backgrounds].
Wei T; Chen XJ; Zhang LY; Zhang AL; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2020 Dec; 22(12):1279-1285. PubMed ID: 33327998
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease monitoring in childhood B lymphoblastic leukemia with t(12;21)(p13;q22); ETV6-RUNX1: concordant results using quantitation of fusion transcript and flow cytometry.
Alm SJ; Engvall C; Asp J; Palmqvist L; Abrahamsson J; Fogelstrand L
Int J Lab Hematol; 2017 Apr; 39(2):121-128. PubMed ID: 28004528
[TBL] [Abstract][Full Text] [Related]
3. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL.
Willemse MJ; Seriu T; Hettinger K; d'Aniello E; Hop WC; Panzer-Grümayer ER; Biondi A; Schrappe M; Kamps WA; Masera G; Gadner H; Riehm H; Bartram CR; van Dongen JJ
Blood; 2002 Jun; 99(12):4386-93. PubMed ID: 12036866
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Two Quantitative PCR-Based Assays for Detection of Minimal Residual Disease in B-Precursor Acute Lymphoblastic Leukemia Harboring Three Major Fusion Transcripts.
Huang YJ; Kuo MC; Jaing TH; Liu HC; Yeh TC; Chen SH; Lin TL; Yang CP; Wang PN; Sheen JM; Chang TK; Chang CH; Hu SF; Huang TY; Wang SC; Wu KH; Chiou SS; Hsiao CC; Shih LY
J Mol Diagn; 2021 Oct; 23(10):1373-1379. PubMed ID: 34325057
[TBL] [Abstract][Full Text] [Related]
5. [Clinical Significance of Minimal Residual Disease in Pediatric Patients with
Xue YJ; Lu AD; Wang Y; Jia YP; Zuo YX; Zhang LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1303-1308. PubMed ID: 37846676
[TBL] [Abstract][Full Text] [Related]
6. [Correlation of E2a-pbx1 expression level with clinical characteristics and early response to treatment in children with acute lymphoblastic leukemia].
Gao C; Li ZG; Zhao W; Wu MY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):569-73. PubMed ID: 18549631
[TBL] [Abstract][Full Text] [Related]
7. Outcome and Prognostic Factors for
Lee JW; Kim SK; Jang PS; Chung NG; Jeong DC; Kim M; Cho B; Kim HK
Cancer Res Treat; 2017 Apr; 49(2):446-453. PubMed ID: 27506214
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and prognostic factors of the chemotherapy regimen of CCLG-ALL-2008 on pediatric acute lymphoblastic leukemia with ETV6-RUNX1 rearrangement].
Liu F; Chen XJ; Guo Y; Yang WY; Chen X; Zhang XY; Zhang RR; Ren YY; Zhu XF
Zhonghua Xue Ye Xue Za Zhi; 2020 Nov; 41(11):896-902. PubMed ID: 33333691
[No Abstract] [Full Text] [Related]
9. High sensitivity and clonal stability of the genomic fusion as single marker for response monitoring in ETV6-RUNX1-positive acute lymphoblastic leukemia.
Hoffmann J; Krumbholz M; Gutiérrez HP; Fillies M; Szymansky A; Bleckmann K; Zur Stadt U; Köhler R; Kuiper RP; Horstmann M; von Stackelberg A; Eckert C; Metzler M
Pediatr Blood Cancer; 2019 Aug; 66(8):e27780. PubMed ID: 31034759
[TBL] [Abstract][Full Text] [Related]
10. Discontinuation of L-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia.
Usami I; Imamura T; Takahashi Y; Suenobu SI; Hasegawa D; Hashii Y; Deguchi T; Hori T; Shimada A; Kato K; Ito E; Moriya-Saito A; Kawasaki H; Hori H; Yumura-Yagi K; Hara J; Sato A; Horibe K;
Int J Hematol; 2019 Apr; 109(4):477-482. PubMed ID: 30689137
[TBL] [Abstract][Full Text] [Related]
11. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.
Huang YJ; Coustan-Smith E; Kao HW; Liu HC; Chen SH; Hsiao CC; Yang CP; Jaing TH; Yeh TC; Kuo MC; Lai CL; Chang CH; Campana D; Liang DC; Shih LY
J Formos Med Assoc; 2017 Oct; 116(10):774-781. PubMed ID: 28063722
[TBL] [Abstract][Full Text] [Related]
12. ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol.
Wang Y; Zeng HM; Zhang LP
Ital J Pediatr; 2018 Aug; 44(1):94. PubMed ID: 30115129
[TBL] [Abstract][Full Text] [Related]
13. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
Borowitz MJ; Devidas M; Hunger SP; Bowman WP; Carroll AJ; Carroll WL; Linda S; Martin PL; Pullen DJ; Viswanatha D; Willman CL; Winick N; Camitta BM;
Blood; 2008 Jun; 111(12):5477-85. PubMed ID: 18388178
[TBL] [Abstract][Full Text] [Related]
15. The prognostic role of E2A-PBX1 expression detected by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in B cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
Hong Y; Zhao X; Qin Y; Zhou S; Chang Y; Wang Y; Zhang X; Xu L; Huang X
Ann Hematol; 2018 Sep; 97(9):1547-1554. PubMed ID: 29705861
[TBL] [Abstract][Full Text] [Related]
16. [Real-time quantitative detection of E2A-PBX1 fusion gene in children with acute lymphoblastic leukemia and its clinical application in minimal residual disease monitoring].
Zhang R; Liao J; Li G; Sun HQ; Shi YJ; Yang JY
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jun; 15(6):440-3. PubMed ID: 23791058
[TBL] [Abstract][Full Text] [Related]
17. PH negative acute lymphoblastic leukemia in adolescents and young adults treated according a MRD adapted BFM ALL IC 2009 protocol: Argentine real-world data on 171 patients.
Ferrari LC; Rivas MM; Navickas AB; Dick H; Mela Osorio MJ; Agamennoni L; Rey IH; Carnelutto NE; Cazap N; Castro MB; Aranguren PN; Fischman LA; Yupanki ML; Milone JH; Fernández II; Moirano MM; Belli CB;
Ann Hematol; 2023 May; 102(5):1087-1097. PubMed ID: 36892593
[TBL] [Abstract][Full Text] [Related]
18. Persistence of TEL-AML1 fusion gene as minimal residual disease has no additive prognostic value in CD 10 positive B-acute lymphoblastic leukemia: a FISH study.
Mosad E; Hamed HB; Bakry RM; Ezz-Eldin AM; Khalifa NM
J Hematol Oncol; 2008 Oct; 1():17. PubMed ID: 18928518
[TBL] [Abstract][Full Text] [Related]
19. [Clinical features and prognosis of ETV6-RUNX1-positive childhood B-precursor acute lymphocyte leukemia].
Zheng YZ; Pan LL; Li J; Chen ZS; Hua XL; Le SH; Zheng H; Chen C; Hu JD
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):45-51. PubMed ID: 33677868
[No Abstract] [Full Text] [Related]
20. [Multicenter evaluation of minimal residual disease monitoring in early induction therapy for treatment of childhood acute lymphoblastic leukemia].
Wu XJ; Liao N; Mai HR; Li XY; Wan WQ; Yang LH; Huang LB; Luo XQ; Tian C; Chen QW; Long XJ; He YY; Wang Y; Li ZG; Xu HG
Zhonghua Er Ke Za Zhi; 2024 Mar; 62(4):337-344. PubMed ID: 38527504
[No Abstract] [Full Text] [Related]
[Next] [New Search]
